vs
Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $167.7M, roughly 1.8× James River Group Holdings, Inc.). James River Group Holdings, Inc. runs the higher net margin — 19.1% vs 12.8%, a 6.3% gap on every dollar of revenue. On growth, James River Group Holdings, Inc. posted the faster year-over-year revenue change (32.4% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -8.7%).
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
JRVR vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $167.7M | $295.9M |
| Net Profit | $32.1M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 14.6% | 18.4% |
| Net Margin | 19.1% | 12.8% |
| Revenue YoY | 32.4% | -6.4% |
| Net Profit YoY | 149.5% | 68.3% |
| EPS (diluted) | $0.59 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $167.7M | $295.9M | ||
| Q3 25 | $172.7M | — | ||
| Q2 25 | $174.8M | $317.0M | ||
| Q1 25 | $172.3M | $316.2M | ||
| Q4 24 | $126.7M | $297.0M | ||
| Q3 24 | $191.5M | $289.5M | ||
| Q2 24 | $188.3M | $306.1M | ||
| Q1 24 | $201.1M | $303.4M |
| Q4 25 | $32.1M | $38.0M | ||
| Q3 25 | $1.0M | — | ||
| Q2 25 | $4.8M | $-17.7M | ||
| Q1 25 | $9.6M | $22.6M | ||
| Q4 24 | $-64.8M | $34.9M | ||
| Q3 24 | $-39.4M | $33.6M | ||
| Q2 24 | $7.6M | $40.6M | ||
| Q1 24 | $15.4M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 14.6% | 18.4% | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 4.2% | -7.5% | ||
| Q1 25 | 9.3% | 12.2% | ||
| Q4 24 | -57.0% | 16.0% | ||
| Q3 24 | -27.1% | 13.8% | ||
| Q2 24 | 10.7% | 15.0% | ||
| Q1 24 | 16.4% | 22.1% |
| Q4 25 | 19.1% | 12.8% | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | 2.7% | -5.6% | ||
| Q1 25 | 5.6% | 7.1% | ||
| Q4 24 | -51.1% | 11.7% | ||
| Q3 24 | -20.6% | 11.6% | ||
| Q2 24 | 4.0% | 13.3% | ||
| Q1 24 | 7.7% | 16.2% |
| Q4 25 | $0.59 | $0.24 | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.06 | $-0.11 | ||
| Q1 25 | $0.16 | $0.14 | ||
| Q4 24 | $-2.44 | $0.22 | ||
| Q3 24 | $-1.10 | $0.21 | ||
| Q2 24 | $0.13 | $0.26 | ||
| Q1 24 | $0.35 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $260.9M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $538.2M | $2.0B |
| Total Assets | $4.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $260.9M | $172.9M | ||
| Q3 25 | $238.8M | — | ||
| Q2 25 | $220.0M | $162.2M | ||
| Q1 25 | $279.4M | $140.7M | ||
| Q4 24 | $362.3M | $177.5M | ||
| Q3 24 | $359.8M | $187.5M | ||
| Q2 24 | $672.5M | $152.9M | ||
| Q1 24 | $305.5M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $538.2M | $2.0B | ||
| Q3 25 | $503.6M | — | ||
| Q2 25 | $492.6M | $1.9B | ||
| Q1 25 | $484.5M | $2.0B | ||
| Q4 24 | $460.9M | $2.1B | ||
| Q3 24 | $530.3M | $2.1B | ||
| Q2 24 | $541.8M | $2.1B | ||
| Q1 24 | $539.5M | $2.0B |
| Q4 25 | $4.9B | $2.5B | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $5.0B | $2.6B | ||
| Q1 25 | $4.9B | $2.6B | ||
| Q4 24 | $5.0B | $2.7B | ||
| Q3 24 | $5.0B | $2.7B | ||
| Q2 24 | $4.7B | $2.7B | ||
| Q1 24 | $5.3B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.8M | — |
| Free Cash FlowOCF − Capex | $-23.6M | — |
| FCF MarginFCF / Revenue | -14.1% | — |
| Capex IntensityCapex / Revenue | 2.9% | — |
| Cash ConversionOCF / Net Profit | -0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-17.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.8M | — | ||
| Q3 25 | $34.3M | — | ||
| Q2 25 | $25.2M | $98.2M | ||
| Q1 25 | $-51.5M | $41.1M | ||
| Q4 24 | $-247.1M | $84.3M | ||
| Q3 24 | $-269.9M | $63.9M | ||
| Q2 24 | $-8.7M | $75.5M | ||
| Q1 24 | $24.1M | $81.0M |
| Q4 25 | $-23.6M | — | ||
| Q3 25 | $33.7M | — | ||
| Q2 25 | $24.7M | $93.3M | ||
| Q1 25 | $-52.7M | $31.0M | ||
| Q4 24 | $-252.0M | $77.5M | ||
| Q3 24 | $-270.8M | $54.7M | ||
| Q2 24 | $-9.3M | $57.5M | ||
| Q1 24 | $23.3M | $64.5M |
| Q4 25 | -14.1% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 14.1% | 29.4% | ||
| Q1 25 | -30.6% | 9.8% | ||
| Q4 24 | -198.9% | 26.1% | ||
| Q3 24 | -141.4% | 18.9% | ||
| Q2 24 | -4.9% | 18.8% | ||
| Q1 24 | 11.6% | 21.3% |
| Q4 25 | 2.9% | — | ||
| Q3 25 | 0.4% | — | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.7% | 3.2% | ||
| Q4 24 | 3.9% | 2.3% | ||
| Q3 24 | 0.4% | 3.2% | ||
| Q2 24 | 0.3% | 5.9% | ||
| Q1 24 | 0.4% | 5.4% |
| Q4 25 | -0.59× | — | ||
| Q3 25 | 33.61× | — | ||
| Q2 25 | 5.29× | — | ||
| Q1 25 | -5.38× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | -1.14× | 1.86× | ||
| Q1 24 | 1.56× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
